Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara Chen

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2015
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphomaJohn E Janik, John C Morris, Deirdre O'Mahony, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2015
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphomaJohn E Janik, John C Morris, Deirdre O'Mahony, et al.
Pageof 6